MedPath

BRAIN Biotech AG Secures €128.88 Million Royalty Monetization Deal for Deucrictibant

• BRAIN Biotech AG заключила сделку по монетизации роялти на сумму до 128,88 млн евро с Royalty Pharma в отношении исследуемого фармацевтического соединения деукриктибант. • BRAIN Biotech получит авансовый платеж в размере 18,41 млн евро, потенциальные промежуточные платежи за нормативное соответствие в размере до 18,42 млн евро и долгосрочные промежуточные платежи, связанные с продажами, в размере до 92,05 млн евро. • Деукриктибант, часть конвейера BioIncubator компании, в настоящее время находится на стадии клинической разработки компанией Pharvaris NV для лечения наследственного ангионевротического отека. • Чистая выручка от этой транзакции будет использована BRAIN Biotech для финансирования будущего роста и погашения кредитов.

BRAIN Biotech AG has finalized a royalty monetization agreement with Royalty Pharma, securing up to €128.88 million for its investigational pharmaceutical compound, deucrictibant. The agreement, announced on September 20, 2024, will provide BRAIN Biotech with significant funding to advance its strategic growth initiatives.

Financial Terms of the Agreement

Under the terms of the agreement, BRAIN Biotech will receive an upfront payment of €18.41 million. Furthermore, the company is eligible for additional regulatory milestone payments of up to €18.42 million, contingent upon the successful progression of deucrictibant through the regulatory approval process. The deal also includes potential long-term sales-related milestone payments, which could reach up to €92.05 million, based on the commercial performance of the drug.

Deucrictibant: A Promising Therapy for Hereditary Angioedema

Deucrictibant, a key asset in BRAIN Biotech’s BioIncubator pipeline, is currently undergoing clinical development by Pharvaris NV (Nasdaq: PHVS). The drug is being investigated for the treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the face, throat, and abdomen.

Strategic Use of Proceeds

BRAIN Biotech intends to allocate the net proceeds from this royalty monetization deal towards future growth funding and the repayment of existing loans. This financial boost will enable the company to further invest in its research and development programs and strengthen its position in the biotechnology sector.

About BRAIN Biotech AG

BRAIN Biotech AG is a leading industrial biotechnology company specializing in the discovery and development of novel biological solutions. The company leverages its expertise in microbial production and enzyme engineering to create innovative products for various industries, including pharmaceuticals, cosmetics, and food.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Brii Bio Acquires Full Rights to BRII-179 and Completes Enrollment for ENRICH Study in HBV

Brii Bio has acquired full intellectual property rights to BRII-179 from VBI Vaccines for $18 million, securing uninterrupted clinical supply and complete ownership.
The acquisition supports Brii Bio's strategy to develop combination treatments for a functional cure for chronic Hepatitis B Virus (HBV) infection.

Neurocrine Biosciences' Crenessity Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Neurocrine Biosciences' Crenessity for treating classic congenital adrenal hyperplasia (CAH) in adults and pediatric patients.
Crenessity is the first corticotropin-releasing factor type 1 receptor (CRF1) antagonist to directly reduce excess adrenocorticotropic hormone (ACTH) and adrenal androgen production.

Alzamend Neuro Strengthens Financial Position, Plans Five Phase II Trials in 2025

Alzamend Neuro reported a significant financial turnaround, with net cash from financing activities reaching $8.3 million for the six months ended October 31, 2024.
The company's stockholder equity improved to $3.8 million, and cash reserves increased to $4.1 million, bolstering its balance sheet.

Quantum BioPharma Advances Lucid-21-302 Clinical Trial for Multiple Sclerosis

Quantum BioPharma's Lucid-21-302, a potential treatment for multiple sclerosis, has progressed to the second cohort dosing phase after positive safety review.
The Phase 1 trial evaluates the safety and pharmacokinetics of Lucid-21-302 in healthy adults, with dosing for the next group expected to begin shortly.

BioNTech to Acquire Biotheus, Bolstering Oncology Pipeline with Bispecific Antibody

BioNTech is set to acquire Biotheus for $800 million upfront, gaining full global rights to BNT327/PM8002, a promising bispecific antibody targeting PD-L1 and VEGF-A.
BNT327/PM8002 has demonstrated encouraging clinical activity across various tumor types, including those with low PD-L1 expression, showing potential to surpass traditional checkpoint inhibitors.

DRI Healthcare Trust Acquires Royalty Interest in KalVista's Seb способов лечения Hereditary Angioedema Drug

DRI Healthcare Trust has acquired a royalty interest in sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), from KalVista Pharmaceuticals.
The agreement includes an upfront payment of US$100 million, potential milestone payments up to US$57 million, and a US$5 million equity investment in KalVista.

MAIA Biotechnology Secures $2.44 Million in Private Placement to Advance THIO Clinical Trials

MAIA Biotechnology has entered into definitive agreements for a $2.44 million private placement to accredited investors and company directors.
The funding involves the sale of 1,079,784 shares of common stock, each paired with a warrant to purchase an additional share.

Sareum Holdings Raises £2.4 Million to Advance TYK2/JAK1 Inhibitor SDC-1801

Sareum Holdings has successfully completed a £2.4 million fundraise to support the development of its lead asset, SDC-1801.
The funding will facilitate longer-term toxicology studies, preparing SDC-1801 for Phase 2 clinical trials in autoimmune diseases.

MaaT Pharma Announces Global Offering to Fund Microbiome Ecosystem Therapies Development

MaaT Pharma, a clinical-stage biotech company, has launched a global offering of approximately 18 million euros to fund the development of its Microbiome Ecosystem Therapies. The offering includes a reserved offering to specific investors and a public offering to retail investors, with the aim of supporting the company's Phase 3 trial for MaaT013 and expanding its pipeline development.

TORL BioTherapeutics Secures $158 Million to Advance ADC Oncology Pipeline

TORL BioTherapeutics has raised $158 million in an oversubscribed Series B-2 financing round to support its antibody-drug conjugate (ADC) oncology pipeline.
The funding will primarily advance the clinical development of TORL-1-23, a first-in-class ADC targeting Claudin 6+ tumors, through Phase 1 and a pivotal Phase 2 trial.

Reference News

[1]
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 ...
webdisclosure.com · Sep 20, 2024

BRAIN Biotech AG concludes royalty monetization deal with Royalty Pharma for up to EUR 128.88 million on investigational...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy